1. GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 3

2. Plasma Levels of Bioactive Intact GLP-1 (9-36)amide After Sitagliptin Administration in T2DM

3. Sitagliptin Reduces Glucose AUC After a Glucose Load

4. Sitagliptin Once Daily Improves Both Fasting and Postmeal Glucose Concentration

5. Sitagliptin Monotherapy and Coadministration With Metformin

6. Sitagliptin: Proportion of Patients Achieving A1C Goals

7. Sitagliptin: Active-Comparator (Glipizide) Add-on to Metformin

8. Sitagliptin: Effect on Baseline A1C

9. Clinical Adverse Events in Active- Comparator Add-on to Metformin Study Patients With Adverse Events, n (%) Sitagliptin 100 mg (n=588) Glipizide (n=584) One or more AEs419(71.3)444(76.0) Drug-related AEs85(14.5)177(30.3) Serious AEs (SAEs)43( 7.3)44( 7.5) Serious drug-related AEs0( 0.0)2( 0.3) Died1( 0.2)2( 0.3) Discontinued due to AEs16( 2.7)21( 3.6) Discontinued due to drug-related AEs8( 1.4)8 Discontinued due to SAEs6( 1.0)7( 1.2) Discontinued due to serious drug-related AEs0( 0.0)0 Stein P. ADA 66th Scientific Sessions; June 9-14, 2006; Washington DC. Late-breaking abstracts.

10. Sitagliptin and Measures of  -Cell Function

11. Sitagliptin: B-Cell Response to Glucose

12. Vildagliptin Studies: Summary 1

13. Sitagliptin Studies: Summary 1